Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis

Dana Lukin, David Faleck, Ronghui Xu, Yiran Zhang, Aaron Weiss, Satimai Aniwan, Siri Kadire, Gloria Tran, Mahmoud Rahal, Adam Winters, Shreya Chablaney, Jenna L. Koliani-Pace, Joseph Meserve, James P. Campbell, Gursimran Kochhar, Matthew Bohm, Sashidhar Varma, Monika Fischer, Brigid Boland, Siddharth SinghRobert Hirten, Ryan Ungaro, Karen Lasch, Eugenia Shmidt, Vipul Jairath, David Hudesman, Shannon Chang, Arun Swaminath, Bo Shen, Sunanda Kane, Edward V. Loftus, Bruce E. Sands, Jean Frederic Colombel, Corey A. Siegel, William J. Sandborn, Parambir S. Dulai

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Background & Aims: We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice. Methods: A multicenter, retrospective, observational cohort study (May 2014 to December 2017) of ulcerative colitis patients treated with vedolizumab or TNF-antagonist therapy. Propensity score weighted comparisons for development of serious adverse events and achievement of clinical remission, steroid-free clinical remission, and steroid-free deep remission. A priori determined subgroup comparisons in TNF-antagonist–naïve and –exposed patients, and for vedolizumab against infliximab and subcutaneous TNF-antagonists separately. Results: A total of 722 (454 vedolizumab, 268 TNF antagonist) patients were included. Vedolizumab-treated patients were more likely to achieve clinical remission (hazard ratio [HR], 1.651; 95% confidence interval [CI], 1.229-2.217), steroid-free clinical remission (HR, 1.828; 95% CI, 1.135-2.944), and steroid-free deep remission (HR, 2.819; 95% CI, 1.496-5.310) than those treated with TNF antagonists. Results were consistent across subgroup analyses in TNF-antagonist–naïve and −exposed patients, and for vedolizumab vs infliximab and vs subcutaneous TNF-antagonist agents separately. Overall, there were no statistically significant differences in the risk of serious adverse events (HR, 0.899; 95% CI, 0.502-1.612) or serious infections (HR, 1.235; 95% CI, 0.608-2.511) between vedolizumab-treated and TNF-antagonist−treated patients. However, in TNF-antagonist−naïve patients, vedolizumab was less likely to be associated with serious adverse events than TNF antagonists (HR, 0.192; 95% CI, 0.049-0.754). Conclusions: Treatment of ulcerative colitis with vedolizumab is associated with higher rates of remission than treatment with TNF-antagonist therapy in routine practice, and lower rates of serious adverse events in TNF-antagonist−naïve patients.

Original languageEnglish
Pages (from-to)126-135
Number of pages10
JournalClinical Gastroenterology and Hepatology
Issue number1
StatePublished - Jan 2022


  • Biologics
  • Comparative Research
  • Health Outcomes


Dive into the research topics of 'Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis'. Together they form a unique fingerprint.

Cite this